Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 11/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094531 | 0.92 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2092026 | 0.92 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2094930 | 0.86 | GNRHR (0.46) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2093577 | 0.86 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2094330 | 0.86 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2094374 | 0.85 | GNRHR (0.50) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2092135 | 0.83 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL4404786 | 0.81 | GNRHR (0.43) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2095546 | 0.78 | GNRHR (0.40) | GNRHRP2RX7MAPTALDH1A1POLB | |
| SCHEMBL2094370 | 0.78 | GNRHR (0.47) | GNRHRP2RX7MAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-7632946-B2 | Naphthyridine-based antibacterial compositions | ABBOTT LABORATORIES (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070088040-A1 | Antibacterial compounds | ABBVIE INC. | 2007-04-19 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088040-A1 | Antibacterial compounds | MRPL21, FDPS, PGLS | GNRHR 4592/4885P2RX7 4199/4885MAPT 3669/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | GNRHR 4352/4885P2RX7 2480/4885MAPT 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.